Dermal Cell News Volume 2.21 | Jun 13 2016

TOP STORY

OX40L Blockade Protects against Inflammation-Driven Fibrosis

Using systemic sclerosis as a prototypic disease, investigators report compelling evidence that blockade of OX40–OX40 ligand (OX40L) is a promising strategy for the treatment of inflammation-driven fibrosis. [Proc Natl Acad Sci USA] Abstract

(Ranked by impact factor of the journal)

DERMAL STEM CELLS & TISSUE REGENERATION

Pre-Administration of PepFect6-MicroRNA-146a Nanocomplexes Inhibits Inflammatory Responses in Keratinocytes and in a Mouse Model of Irritant Contact Dermatitis

PepFect6 was shown to form unimodal nanocomplexes with miR-146a mimic that entered into human primary keratinocytes, where miR-146a inhibited the expression of its direct targets from the NF-κB pathway and the genes known to be activated by NF-κB, C-C motif ligand 5 and interleukin-8. [J Control Release] Abstract

Inhibition of β-Catenin Signaling in Dermal Fibroblasts Enhances Hair Follicle Regeneration during Wound Healing

To understand the postnatal loss of hair forming ability, scientists made small (2mm diameter) circular wounds and monitored hair follicle formation at the wound site. [Development] Abstract | Full Article

Self-Assembling Peptide Hydrogel Scaffolds Support Stem Cell-Based Hair Follicle Regeneration

Investigators examined the effect of self-assembling peptide hydrogels in supporting skin derived precursors in hair follicle neogenesis. [Nanomedicine] Abstract

Juglone Ameliorates Skin Wound Healing by Promoting Skin Cell Migration through Rac1/Cdc42/PAK Pathway

Researchers investigated the wound healing potential of juglone, a naturally occurring Pin1 inhibitor found in walnuts. [Wound Repair Regen] Abstract

Preparation of Biodegradable Gelatin/PVA Porous Scaffolds for Skin Regeneration

The effect of polymer concentration, gelatin/poly (vinyl alcohol) (gelatin/PVA) ratio, and glutaraldehyde/gelatin ratio was investigated on morphology of pores, swelling ratio, biodegradation, and skin cell culture. [Artif Cells Nanomed Biotechnol] Abstract

SKIN CANCERS & DISORDERS

Neogenin Defined as a GD3-Associated Molecule by Enzyme-Mediated Activation of Radical Sources Confers Malignant Properties via Intra-Cytoplasmic Domain in Melanoma Cells

To investigate mechanisms for increased malignant properties in malignant melanomas by gangliosdide GD3, enzyme-mediated activation of radical sources and subsequent mass spectrometry were performed using an anti-GD3 antibody, and GD3-positive and GD3-negative melanoma cell lines. [J Biol Chem] Abstract | Full Article

Metformin Is Also Effective on Lactic Acidosis-Exposed Melanoma Cells Switched to Oxidative Phosphorylation

The authors demonstrated that melanoma cells exposed to an acidic extracellular microenvironment, pH 6.6-6.8, shift to an oxidative phosphorylation metabolism. [Cell Cycle] Abstract

Use of a Tissue Engineered Human Skin Model to Investigate the Effects of Wounding and of an Anti-Inflammatory on Melanoma Cell Invasion

Researchers investigated the use of an anti-inflammatory on melanoma invasion. To do this they developed a wounded and inflamed in vitro 3D melanoma model in which to investigate the use of an anti-inflammatory on melanoma invasion. [PLoS One] Full Article

Metabolic Rewiring in Melanoma

The authors discuss the nature of metabolic alterations that underlie melanoma development and affect its response to therapy. [Oncogene] Abstract

Visit our reviews page to see a complete list of reviews in the dermal cell research field.

Can-Fite Submits Psoriasis Phase III Protocol and Registration Plan to EMA for Piclidenoson (CF101)

Can-Fite BioPharma Ltd. has submitted its protocol design to the European Medicines Agency (EMA) for a Phase III trial and Registration Plan for the company’s lead compound Piclidenoson (CF101) in the treatment of psoriasis. [Can-Fite BioPharma Ltd. (PR Newswire Association LLC.)] Press Release

Novartis Combination Therapy Tafinlar^® + Mekinist^® Demonstrates Overall Survival Benefit at Three-Year Follow-Up in Patients with Advanced Melanoma

Novartis announced data from a Phase III study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive advanced melanoma when treated with the first-line combination of Tafinlar^® + Mekinist^® compared to Tafinlar monotherapy [Novartis Pharmaceuticals Corporation] Press Release

NEW Gordon Research Conference – Tissue Niches & Resident Stem Cells in Adult Epithelia
August 7-12, 2016
Hong Kong, China

Visit our events page to see a complete list of events in the dermal cell community.

NEW Cancer Scientists (Hamad bin Khalifa University)

Research Scientist – Hair Biophysics (L’Oreal)

Postdoctoral Scientist – Skin Cancer and Aging Group (Cancer Research UK Manchester Institute)

Associate Professor/Professor – Dermatology (The University of Texas MD Anderson Cancer Center)

Scientist – Target Validation (Innate Pharma)

Postdoctoral Positions – Stem Cell Biology and Regenerative Medicine (University of Southern California)

Medical Science Liaison Associate – Skin Diseases (Biofrontera Inc.)

Postdoctoral Fellow – Biology (California Institute for Biomedical Research)

Postdoctoral Positions – Immunology, Cancer, and Stem Cells (University of Connecticut)

Postdoctoral Position – Cancer Biology/Immunology (The University of Texas MD Anderson Cancer Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Dermal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.